Processa Pharmaceuticals PCSA Stock
Processa Pharmaceuticals Price Chart
Processa Pharmaceuticals PCSA Financial and Trading Overview
| Processa Pharmaceuticals stock price | 1.67 USD |
| Previous Close | 0.68 USD |
| Open | 0.66 USD |
| Bid | 0 USD x 3100 |
| Ask | 0 USD x 800 |
| Day's Range | 0.55 - 0.66 USD |
| 52 Week Range | 0.36 - 3.83 USD |
| Volume | 538.23K USD |
| Avg. Volume | 111.95K USD |
| Market Cap | 14.72M USD |
| Beta (5Y Monthly) | 0.134859 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.48 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3 USD |
PCSA Valuation Measures
| Enterprise Value | 6.1M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.4878049 |
| PEG Ratio (5 yr expected) | -0.05 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.4527847 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.3 |
Trading Information
Processa Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.134859 |
| 52-Week Change | -77.27% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.83 USD |
| 52 Week Low | 0.36 USD |
| 50-Day Moving Average | 0.61 USD |
| 200-Day Moving Average | 1.3 USD |
PCSA Share Statistics
| Avg. Volume (3 month) | 111.95K USD |
| Avg. Daily Volume (10-Days) | 308.37K USD |
| Shares Outstanding | 24.53M |
| Float | 20.02M |
| Short Ratio | 2.89 |
| % Held by Insiders | 16.37% |
| % Held by Institutions | 4.88% |
| Shares Short | 201.28K |
| Short % of Float | 0.99% |
| Short % of Shares Outstanding | 0.82% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:7 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -71.91% |
| Return on Equity (ttm) | -169.082% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -20345614 USD |
| Net Income Avi to Common (ttm) | -28219172 USD |
| Diluted EPS (ttm) | -1.65 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 10.74M USD |
| Total Cash Per Share (mrq) | 0.44 USD |
| Total Debt (mrq) | 210.52K USD |
| Total Debt/Equity (mrq) | 2.08 USD |
| Current Ratio (mrq) | 5.655 |
| Book Value Per Share (mrq) | 0.413 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -9916287 USD |
| Levered Free Cash Flow (ttm) | -2580668 USD |
Profile of Processa Pharmaceuticals
| Country | United States |
| State | MD |
| City | Hanover |
| Address | 7380 Coca Cola Drive |
| ZIP | 21076 |
| Phone | 443 776 3133 |
| Website | https://www.processapharmaceuticals.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 15 |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytidine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.
Q&A For Processa Pharmaceuticals Stock
What is a current PCSA stock price?
Processa Pharmaceuticals PCSA stock price today per share is 1.67 USD.
How to purchase Processa Pharmaceuticals stock?
You can buy PCSA shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Processa Pharmaceuticals?
The stock symbol or ticker of Processa Pharmaceuticals is PCSA.
Which industry does the Processa Pharmaceuticals company belong to?
The Processa Pharmaceuticals industry is Biotechnology.
How many shares does Processa Pharmaceuticals have in circulation?
The max supply of Processa Pharmaceuticals shares is 2.86M.
What is Processa Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Processa Pharmaceuticals PE Ratio is now.
What was Processa Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Processa Pharmaceuticals EPS is -8.48 USD over the trailing 12 months.
Which sector does the Processa Pharmaceuticals company belong to?
The Processa Pharmaceuticals sector is Healthcare.
Processa Pharmaceuticals PCSA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}